Qlucore invests in development and USA

Rights issue and development loan fund expansion in software team and US salesforce

Qlucore, a world leader in the development of bioinformatics software enhances its financial position with a combination of a rights issue and a development loan from Swedish regional development fund ALMI. Investment from the two sources is EURO 545,000. This injection of capital will increase the development team at the firm’s head office in Lund, Sweden and increase the Qlucore sales force in the USA.

Carl-Johan Ivarsson, President, Qlucore commented “We are grateful to ALMI and the shareholders of Qlucore for supporting the growth ambitions of the firm’s management. This investment will enable us to significantly enhance the speed of Qlucore’s continued growth by increasing the development and sales teams. This will be particularly noticeable in the US market which we have identified as key to the future success of Qlucore.”

Extensive use by current clients is providing a platform for increased growth. This is exemplified by the number of published scientific articles that reference Qlucore’s use which has now passed the 270 mark, showing the increasing popularity of the software amongst the international scientific research community. The variety of research undertaken using Qlucore Omics Explorer is staggering, and some examples from 2015 are below. For a full list of articles referencing Qlucore see here

• Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers

• Genetic analysis of Anaplastic Thyroid Cancer

• Extracellular matrix proteins as drivers of inflammation in rheumatoid arthritis

• Network Cluster Analysis of Protein–Protein Interaction Network–Identified Biomarker for Type 2 Diabetes

• A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer

• Serum biomarker profile can predict the outcome of acute HCV infection